{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=19&q=fallopian+tube",
    "query": {
      "q": "fallopian tube",
      "condition": "Ovarian Cancer",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 739,
    "total_pages": 74,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=20&q=fallopian+tube&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=18&q=fallopian+tube&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T11:53:48.689Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07220512",
      "title": "The Better, Harder, Faster, Stronger Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Frailty at Older Adults",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Cognitive Dysfunction",
        "Neoadjuvant Chemotherapy"
      ],
      "interventions": [
        {
          "name": "data collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "55 Years and older · Female only"
      },
      "enrollment_count": 35,
      "start_date": "2025-07-28",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-10-14T11:53:48.689Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220512"
    },
    {
      "nct_id": "NCT03579316",
      "title": "Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Adavosertib",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Ceralasertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2018-12-07",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-14T11:53:48.689Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03579316"
    },
    {
      "nct_id": "NCT01139957",
      "title": "Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Carcinoma",
        "Fallopian Tube Carcinoma",
        "Ovarian Neoplasm",
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Evaluation of Cancer Risk Factors",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Study of High Risk Factors",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "30 Years and older · Female only"
      },
      "enrollment_count": 1916,
      "start_date": "2010-06-07",
      "completion_date": "2020-04-10",
      "has_results": false,
      "last_update_posted_date": "2020-09-02",
      "last_synced_at": "2026-10-14T11:53:48.689Z",
      "location_count": 141,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 106 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01139957"
    },
    {
      "nct_id": "NCT04739800",
      "title": "Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Mucinous Adenocarcinoma",
        "Ovarian Seromucinous Carcinoma",
        "Platinum-Refractory Fallopian Tube Carcinoma",
        "Platinum-Refractory Ovarian Carcinoma",
        "Platinum-Refractory Primary Peritoneal Carcinoma",
        "Recurrent Fallopian Tube Clear Cell Adenocarcinoma",
        "Recurrent Fallopian Tube Endometrioid Adenocarcinoma",
        "Recurrent Fallopian Tube High Grade Serous Adenocarcinoma",
        "Recurrent Fallopian Tube Mucinous Adenocarcinoma",
        "Recurrent Fallopian Tube Transitional Cell Carcinoma",
        "Recurrent Fallopian Tube Undifferentiated Carcinoma",
        "Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma",
        "Recurrent Ovarian Clear Cell Adenocarcinoma",
        "Recurrent Ovarian Endometrioid Adenocarcinoma",
        "Recurrent Ovarian High Grade Serous Adenocarcinoma",
        "Recurrent Ovarian Low Grade Serous Adenocarcinoma",
        "Recurrent Ovarian Mucinous Adenocarcinoma",
        "Recurrent Ovarian Seromucinous Carcinoma",
        "Recurrent Ovarian Transitional Cell Carcinoma",
        "Recurrent Ovarian Undifferentiated Carcinoma",
        "Recurrent Platinum-Resistant Fallopian Tube Carcinoma",
        "Recurrent Platinum-Resistant Ovarian Carcinoma",
        "Recurrent Platinum-Resistant Primary Peritoneal Carcinoma",
        "Recurrent Primary Peritoneal Clear Cell Adenocarcinoma",
        "Recurrent Primary Peritoneal Endometrioid Adenocarcinoma",
        "Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma",
        "Recurrent Primary Peritoneal Transitional Cell Carcinoma",
        "Recurrent Primary Peritoneal Undifferentiated Carcinoma",
        "Refractory Fallopian Tube Clear Cell Adenocarcinoma",
        "Refractory Fallopian Tube Endometrioid Adenocarcinoma",
        "Refractory Fallopian Tube High Grade Serous Adenocarcinoma",
        "Refractory Fallopian Tube Mucinous Adenocarcinoma",
        "Refractory Fallopian Tube Transitional Cell Carcinoma",
        "Refractory Fallopian Tube Undifferentiated Carcinoma",
        "Refractory Low Grade Fallopian Tube Serous Adenocarcinoma",
        "Refractory Ovarian Clear Cell Adenocarcinoma",
        "Refractory Ovarian Endometrioid Adenocarcinoma",
        "Refractory Ovarian High Grade Serous Adenocarcinoma",
        "Refractory Ovarian Low Grade Serous Adenocarcinoma",
        "Refractory Ovarian Mucinous Adenocarcinoma",
        "Refractory Ovarian Seromucinous Carcinoma",
        "Refractory Ovarian Transitional Cell Carcinoma",
        "Refractory Ovarian Undifferentiated Carcinoma",
        "Refractory Primary Peritoneal Clear Cell Adenocarcinoma",
        "Refractory Primary Peritoneal Endometrioid Adenocarcinoma",
        "Refractory Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma",
        "Refractory Primary Peritoneal Transitional Cell Carcinoma",
        "Refractory Primary Peritoneal Undifferentiated Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cediranib Maleate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography with Contrast",
          "type": "PROCEDURE"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Liposomal Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Topotecan Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2021-06-10",
      "completion_date": "2027-06-25",
      "has_results": true,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-14T11:53:48.689Z",
      "location_count": 384,
      "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 288 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04739800"
    },
    {
      "nct_id": "NCT02419495",
      "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Fallopian Tube Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Metastatic Renal Cell Carcinoma",
        "Ovarian Carcinoma",
        "Pathologic Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Primary Peritoneal Carcinoma",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Triple-Negative Breast Carcinoma",
        "Unresectable Lung Non-Small Cell Carcinoma",
        "Unresectable Melanoma",
        "Unresectable Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Selinexor",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 221,
      "start_date": "2015-06-26",
      "completion_date": "2024-09-16",
      "has_results": false,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-10-14T11:53:48.689Z",
      "location_count": 5,
      "location_summary": "Conroe, Texas • Houston, Texas • League City, Texas + 1 more",
      "locations": [
        {
          "city": "Conroe",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "League City",
          "state": "Texas"
        },
        {
          "city": "Sugar Land",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02419495"
    },
    {
      "nct_id": "NCT00066404",
      "title": "Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant adenovirus-hIFN-beta",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "2003-04",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2020-05-13",
      "last_synced_at": "2026-10-14T11:53:48.689Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00066404"
    },
    {
      "nct_id": "NCT01744821",
      "title": "Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Arm A: Vitamin D3 Group",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 7,
      "start_date": "2012-10",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2015-07-23",
      "last_synced_at": "2026-10-14T11:53:48.689Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Evanston, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01744821"
    },
    {
      "nct_id": "NCT00407407",
      "title": "ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fallopian Tube Neoplasms",
        "Peritoneal Neoplasms",
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "ABI-007",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 6,
      "start_date": "2006-11-01",
      "completion_date": "2008-02-01",
      "has_results": false,
      "last_update_posted_date": "2019-10-18",
      "last_synced_at": "2026-10-14T11:53:48.689Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00407407"
    },
    {
      "nct_id": "NCT00035100",
      "title": "EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Neoplasms",
        "Peritoneal Neoplasms",
        "Fallopian Tube Neoplasms"
      ],
      "interventions": [
        {
          "name": "epothilone b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 54,
      "start_date": "2001-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-04-16",
      "last_synced_at": "2026-10-14T11:53:48.689Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00035100"
    },
    {
      "nct_id": "NCT01144442",
      "title": "WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Hyperthermic intraperitoneal chemotherapy with Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Isotonic saline (perfusate)",
          "type": "OTHER"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 90 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2010-07-27",
      "completion_date": "2015-05-01",
      "has_results": true,
      "last_update_posted_date": "2019-07-30",
      "last_synced_at": "2026-10-14T11:53:48.689Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01144442"
    }
  ]
}